Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Abbott
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Pathologically documented NSCLC
Locally advanced (Stage III) or metastatic (Stage IV) NSCLC
Only one prior anti-tumor treatment regimen in the non-curative setting (i.e., 2nd-line therapy)
Only one prior anti-tumor treatment regimen in the curative setting
Progressive disease following the previous anti-tumor treatment regimen
Measurable disease by RECIST criteria
Brain metastasis must be stable and well-controlled
ECOG performance score 0-2All anti-tumor therapy discontinued at least 3 weeks prior to study entryAll adverse events from prior treatment are resolved or stableAdequate hematologic, renal, and hepatic functionFemales must not be pregnantWilling to take adequate measures to prevent pregnancyLife expectancy of at least 3 monthsAble to complete the Quality of Life questionnaireVoluntarily signed informed consent
Only one prior anti-tumor treatment regimen in the curative setting
Progressive disease following the previous anti-tumor treatment regimen
Measurable disease by RECIST criteria
Brain metastasis must be stable and well-controlled
ECOG performance score 0-2
All anti-tumor therapy discontinued at least 3 weeks prior to study entry
All adverse events from prior treatment are resolved or stable
Adequate hematologic, renal, and hepatic function
Females must not be pregnant
Willing to take adequate measures to prevent pregnancy
Life expectancy of at least 3 months
Able to complete the Quality of Life questionnaire
Voluntarily signed informed consent
You may not be if
Greater that Grade 1 neurological findings
Allergy to sulfa medications
Previous treatment with ABT-751 or docetaxel
Receipt of more than one investigational agent for NSCLC
Significant weight loss (\>10%) within 6 weeks of study entry
Glucose-6-phosphate dehydrogenase deficiency or porphyria
Significant systemic disease that would adversely affect participation
Class 3-4 New York Heart Association classification status
Other cancers except in situ carcinoma of the cervix, basal or squamous cell skin cancer, or any other cancer considered adequately treated and cured by the investigator
Clareo Health | A Phase 2 Study Evaluating ABT-751 in Combination With Taxotere in Advanced Non-Small Cell Lung Cancer
